EGFR/HER2 EXON 20 INSERTION MUTATION

Clinical trials for EGFR/HER2 EXON 20 INSERTION MUTATION explained in plain language.

Never miss a new study

Get alerted when new EGFR/HER2 EXON 20 INSERTION MUTATION trials appear

Sign up with your email to follow new studies for EGFR/HER2 EXON 20 INSERTION MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

First human trial launches for targeted lung cancer treatment

Disease control Recruiting now

This study is testing a new drug called STX-721/PFL-721 for people with advanced non-small cell lung cancer that has specific genetic mutations (EGFR or HER2 exon 20 insertions). The trial aims to find the safest and most effective dose while checking if the drug can shrink tumor…

Matched conditions: EGFR/HER2 EXON 20 INSERTION MUTATION

Phase: PHASE1, PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

EGFR/HER2 EXON 20 INSERTION MUTATION

Get alerted when new EGFR/HER2 EXON 20 INSERTION MUTATION trials appear

First human trial launches for targeted lung cancer treatment